Jyseleca®

Active substance     Filgotinib
Holder Impatients N.V. (trading as myTomorrows) on behalf of Alfasigma S.p.A.
Status Running
Indication Subjects with axial spondyloarthritis (axSpA) who have participated in the previous filgotinib clinical trial OLINGUITO (GLPG0634-CL-336) in Belgium and who, based on the clinical judgement of their treating physician, may benefit from continued treatment.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 26/05/2026

 

Last updated on